<DOC>
	<DOCNO>NCT02250794</DOCNO>
	<brief_summary>The purpose study test whether combination two pill commonly use treat outpatient diabetes call metformin sitagliptin ( januvia ) could provide successful control blood sugar level patient type 2 diabetes hospitalization treatment general medical condition . Both metformin sitagliptin currently approve Food Drug Administration treatment type 2 diabetes , little experience exists use hospitalized patient . The current standard practice use insulin injection control blood sugar hospitalize patient type 2 diabetes . This study compare use metformin tablet twice per day along sitagliptin tablet per day daily insulin injection patient type 2 diabetes hospitalization , study well blood sugar level control .</brief_summary>
	<brief_title>Metformin Sitagliptin Therapy Adult Patients With Type 2 Diabetes Admitted General Medical Unit</brief_title>
	<detailed_description>We propose trial evaluate whether in-hospital glycemic control , measure mean daily glucose concentration frequency hypoglycemic event , different treatment metformin sitagliptin combination treatment glargine insulin daily rapid-acting insulin analog meal patient type 2 diabetes . Hyperglycemia associate increased mortality , prolonged hospitalization increase complication infection ( 1 ) . Consensus guideline recommend long-acting basal insulin meal-time bolus insulin therapy inpatient blood glucose management . These basal bolus regimen labor intensive , require multiple injection day , cause hypoglycemia . A study institution patient admit hospital treat basal bolus insulin protocol find incidence hypoglycemia ( blood glucose less 70 mg/dl ) 20 % patient stay ( 2 ) . A strategy inpatient blood glucose management less risk hypoglycemia need . We propose trial use two oral medication metformin sitagliptin low blood sugar without risk hypoglycemia . Metformin first-line therapy outpatient management type 2 diabetes . It long-standing evidence safety efficacy . It decrease hepatic glucose production increase insulin-mediated glucose utilization muscle liver . A Cochrane Review 29 trial metformin monotherapy compare oral agent , insulin , diet , placebo show reduction cardiovascular event all-cause mortality metformin ( 3 ) . Sitagliptin Dipeptidyl-peptidase-4 ( DPP-4 ) inhibitor approve FDA monotherapy combination metformin treatment type 2 diabetes . Metformin sitagliptin active within 24 hour initiation cause hypoglycemia . Sitagliptin work slow inactivation glucagon-like peptide-1 ( GLP-1 ) . GLP-1 stimulates glucose dependent secretion endogenous insulin meal . A recent preliminary study support use sitagliptin inpatient glucose management . This trial include 90 patient type 2 diabetes admit general medicine surgery service . It randomize patient one three group : sitagliptin alone , sitagliptin plus long-acting insulin ( glargine ) , basal bolus insulin regimen . The study select patient mild moderate diabetes include patient diabetes controlled diet alone , combination oral antidiabetic agent , total daily insulin dose ≤ 0.4 units/kg prior admission . Patients eligible blood sugar 140 - 400 mg/dl . Patients three group receive supplemental ( correction ) dose rapid-acting insulin meal bedtime blood glucose &gt; 140 mg/dL . Glycemic control improve similarly treatment group , 100 % patient sitagliptin alone group require one injection rapid-acting insulin correct hyperglycemia ( 4 ) . This result suggest sitagliptin alone insufficient therapy treat hyperglycemia population . We recruit similar population patient , add metformin improve blood sugar control . Our sitagliptin metformin group receive supplemental dos rapid-acting insulin purpose trial evaluate regimen without risk hypoglycemia . Metformin safe patient adequate renal function . The current prescribing information metformin use permit serum creatinine ≤ 1.4 mg/dL woman ≤ 1.5 mg/dL men equivalent GFR ≥ 60 ml/min ( 5 ) . It excrete kidney therefore potentially accumulate patient renal failure . Metformin work inhibit gluconeogenesis—a process utilizes lactic acid produce glucose . Thus , accumulation medication , could predispose patient lactic acidosis . The incidence lactic acidosis metformin extremely low . A systematic review 347 randomized trial prospective cohort study represent 70,490 patient-years metformin use 55,451 patient-years non-metformin group reveal case lactic acidosis . Almost half study allow inclusion patient serum creatinine 1.5 mg/dL , 97 % study allow inclusion patient least one contraindication metformin therapy ( 6 ) . Another trial evaluate risk lactic acidosis metformin 393 patient renal insufficiency , serum creatinine level 1.5 2.5 mg/dl ( mean level 1.8 mg/dl ) find case lactic acidosis four year trial duration ( 7 ) . Most case lactic acidosis patient take metformin associate shock tissue hypoxia . Elevated lactate patient may relate metformin . This support fact lactic acidosis occur frequently metformin user user anti-diabetes medication ( 8 ) . Also , metformin level correlate lactate level mortality suggest underlying disease likely cause acidosis metformin ( 9 ) . However theoretical concern exceedingly rare complication exclude metformin use hospitalize patient . The recognition rarity lactic acidosis among user metformin renal insufficiency change recommendation allow use patient mild moderate renal insufficiency . Current guideline use estimate GFR ( eGFR ) accurate approximation renal function serum creatinine . The current recommendation American Diabetes Association state metformin use full dos ( 2000 mg/day ) long eGFR &gt; 45 ml/min serum creatinine monitor . If eGFR &lt; 45ml/min , maximal dose 1000 mg/day advise , serum creatinine monitoring . Metformin use eGFR &lt; 30 ml/min ( 10 ) . The American College Radiology recently update guideline use metformin patient receive IV contrast medium ( 11 ) . A prior guideline recommend hold metformin 4 day surround IV contrast administration evaluate contrast-induced acute kidney injury . This guideline contribute practice discontinue metformin hospitalization due commonness radiology study use IV contrast . There drug interaction metformin contrast medium effect metformin renal function . Given risk contrast-induced acute kidney injury low patient normal renal function co-morbidities , revise ( 2013 ) American College Radiology guideline recommend metformin continue without need evaluate renal function follow contrast medium . In presence co-morbidities increase risk develop acidosis ( liver dysfunction , alcohol abuse , heart failure , myocardial peripheral muscle ischemia , sepsis severe infection ) , new guideline recommend hold metformin two day IV contrast administration . Our study include patient without co-morbidities normal renal function ( eGFR &gt; 60 ml/min ) . All subject serum creatinine measure daily , metformin discontinue event acute kidney injury . Since metformin safe effective glucose management patient type 2 diabetes normal renal function , propose continuation hospitalization . This study include adult patient type 2 diabetes currently treat metformin alone combination anti-diabetic agent include low dose insulin . All subject normal renal function ( eGFR &gt; 60 ml/min ) comorbidities increase risk acidosis . This prospective , randomize control trial compare metformin sitagliptin ( cause hypoglycemia ) usual insulin therapy , know cause hypoglycemia . This study possible implication improve safety therapy hospitalize patient type 2 diabetes .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Insulin Lispro</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>1 . Males female age 18 80 year admit general medicine service require intensive care expect require surgery . 2 . Type 2 diabetes ≥ 3 month treat metformin ( ≥ 1000 mg/day ) alone metformin ( ≥ 1000 mg/day ) glimepiride , glyburide , glipizide , saxagliptin , sitagliptin , linagliptin , alogliptin , repaglinide , nateglinide , pioglitazone , exenatide , liraglutide , total daily dose insulin ≤ 0.4 units/kg/day prior admission . 3 . Blood glucose &gt; 140 mg &lt; 400 mg/dL 1 . Acute critical illness expect require admission critical care unit 2 . Patients expect require major surgery ( require general anesthesia ) 3 . Patients expect require gastrointestinal suction 4 . Patients treat less 1000 mg/day metformin prior admission 5 . Patients expect kept nothing mouth ( NPO ) &gt; 2448 hour admission 6 . Patients impaired renal function estimate GFR le 60 ml/min base Modification Diet Renal Disease ( MDRD ) Study equation . 7 . Clinically significant liver dysfunction current alcohol abuse 8 . Uncompensated heart failure 9 . Myocardial peripheral muscle ischemia 10 . Sepsis severe infection 11 . Treatment glucocorticoid great prednisone 5 mg daily equivalent 12 . Mental condition render subject unable understand nature , scope , possible consequence study 13 . Pregnancy breast‑feeding time enrollment study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>diabetes mellitus</keyword>
	<keyword>inpatient management</keyword>
	<keyword>metformin</keyword>
	<keyword>sitagliptin</keyword>
</DOC>